Covid19 Clinical Trial
Official title:
Perceptions of Netizens Regarding COVID-19 Information & Information Sources: A Cross Sectional Study
COVID-19 Infection was characterized as a Pandemic by WHO on the 11th of March 2020.1 After
this there were all possible worldwide efforts to increase awareness in the general
population about the COVID-19 Infection signs, symptoms, mode of transmission and prevention.
The information was spread across all possible mass media communication channels. There were
constant updates regarding the data of newly infected cases, deaths, and recoveries. This
cross sectional study is conducted with the following objectives:
1. To understand the netizens perception regarding the sources of information available on
COVID-19.
2. To understand the netizens populations perception regarding the available information on
COVID-19.
Mass media plays a significant role in public outreach and create awareness. Various mass
media has their individual reach to the general public. In the current world of information
technology availability of information is not an issue. There is in fact excessive
availability of information. What makes a big difference is that RIGHT information delivery
on RIGHT time and within RIGHT time. After WHO characterized COVID-19 infection as pandemic,
mass media played a significant role in creating awareness regarding COVID-19 infection
signs, symptoms, mode of transmission and its prevention. There were constant updates in
various mass media regarding the data of newly infected cases, deaths, and recoveries.
COVID-19 Pandemic has created fears, anxiety, and worries among the general population. There
was information given to general public regarding treatment drugs and possibility of vaccine
for COVID-19 infection. This created a ray of hope in many. So information in various mass
media sources had different types of impact on general population thoughts.
This cross sectional study is conducted with the following objectives:
1. To understand the general populations perception regarding the sources of information
available on COVID-19.
2. To understand the general populations perception regarding the available information on
COVID-19.
This Cross sectional study utilizes an electronic google form to get responses from netizens
of Al Qassim province of Saudi Arabia regarding the perception of COVID-19 information and
information sources. All the questions in the survey are compulsory answerable questions. The
settings in the google form are set so that a single respondent can limit the survey response
to single time. The Survey Questionnaire contained following sections:
Section I: Minimum required personal details Section II: 10 Questions regarding the source of
COVID-19 information Section III: 6 Questions regarding perception of the COVID-19
information
The questionnaire also carried the following disclaimer:
"This Survey will not Collect your Name, Email, Location, and Phone number. We pledge that
the data obtained by this survey is for Educational purpose & scientific knowledge
enhancement only. The data will not be transferred or shared with any other third party for
commercial interest."
The very first part of the Questionnaires seeks responders' consent for giving responses to
the survey questions. participation Section II & III contained all closed ended questions.
The Google form link is shared to the netizens of Al Qassim province across relevant Social
media platforms.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |